Antidiabetic medications in patients with heart failure

Hayek, Marylene M Samia El; Beydoun, Maya; Azar, Sami T.

doi:10.23736/s0391-1977.16.02349-x

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( Therefore, the CVOTs (CardioVascular Outcome Trials) are designed to analyze the safety of glucose-lowering agents concerning three-point Major Adverse Cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and nonfatal stroke. The CVOTs relating to the SGLT2 inhibitors have shown that these agents are safe in terms of three-point MACE and may also be protective against HF-related events, independent of atherosclerotic cardiovascular disease (CVD) or the presence of HF at baseline [9,10]. SGLT2i is a relatively new class of drugs used for the management of T2D, and they have shown potential benefit in HFrEF (Figures 1 and 2) [11].…”

Section: Currently Approved Pharmacological Treatment For Heartmentioning

confidence: 99%

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective

et al. 2022

View full text Add to dashboard Cite

The sodium-glucose transporter 2 inhibitors (SGLT2i) are a relatively new class of medication used in the management of type 2 diabetes. Recent clinical trials and research have demonstrated this class’s effectiveness in treating heart failure, since they reduce the risk of cardiovascular events, hospitalization, and mortality. The mechanism by which they do so is unclear; however, SGLT2i inhibit the tubular reabsorption of glucose, lowering the interstitial volume. This mechanism leads to a reduction in blood pressure and an improvement of endothelial function. As a result, improvements in hospitalization and mortality rate have been shown. In this review, we focus on the primary outcome of the clinical trials designed to investigate the effect of SGLT2i in heart failure, regardless of patients’ diabetic status. Furthermore, we compare the various SGLT2i regarding their risk reduction to investigate their potential as a treatment option for patients with reduced ejection fraction and preserved ejection fraction.

show abstract

Section: Currently Approved Pharmacological Treatment For Heartmentioning

confidence: 99%

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective

et al. 2022

View full text Add to dashboard Cite

show abstract

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Brito

Bettencourt

Carvalho

et al. 2020

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and cardiovascular mortality. These benefits appear to be independent of glycaemic control and have recently been demonstrated in the HF population with reduced ejection fraction (HFrEF), with or without T2D. This comprehensive, evidence-based review focuses on the published studies concerning HF outcomes with SGLT2i, discussing issues that may underlie the different results, along with the impact of these new drugs in clinical practice. The potential translational mechanisms behind SGLT2i cardio-renal benefits and the information that ongoing studies may add to the already existing body of evidence are also reviewed. Finally, we focus on practical management issues regarding SGLT2i use in association with other T2D and HFrEF common pharmacological therapies. Safety considerations are also highlighted. Considering the paradigm shift in T2D management, from a focus on glycaemic control to a broader approach on cardiovascular protection and event reduction, including the potential for wide SGLT2i implementation in HF patients, with or without T2D, we are facing a promising time for major changes in the global management of cardiovascular disease.

show abstract

Antidiabetic medications in patients with heart failure

Cited by 2 publications

References 0 publications

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Contact Info

Product

Resources

About